Clinical Trial Update: Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of nivolumab with BMS-986253 in hormone-sensitive prostate cancer has posted results. The trial status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Prostate Cancer

Drugs mentioned

• BMS-986253 (BMS-986253)
• nivolumab (nivolumab)

Snippet

Sponsor: Mark Stein | Conditions: Prostate Cancer, Adenocarcinoma of the Prostate | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-29